This Week in Family Medicine — May 14, 2026

Welcome to This Week in Family Medicine. This week we're covering 10 notable papers spanning the long-term consequences of viral infections, the expanding scope of health guidelines to include public and planetary health, and new insights into foundational pillars of wellness like sleep and mental health. Let's dive in. We begin with two studies that bookend the experience of respiratory viral infections, one looking at long-term consequences and the other at immediate prevention. A striking study in *Cell* suggests a causal link between prior severe viral pneumonia and subsequent lung cancer [9]. Researchers analyzed data from patients previously hospitalized with severe COVID-19 and found an increased risk of developing lung cancer later on. To explore the mechanism, they turned to multiple murine models. They found that severe respiratory viral infections accelerated lung cancer growth. It appears the initial infection permanently reprograms the lung into a pro-tumor microenvironment, characterized by a sustained accumulation of tumor-associated neutrophils and a generally immunosuppressive state. The investigators observed persistent changes in the chromatin of immune and structural cells, creating an inflammatory memory that promotes tumor growth. This is a crucial finding for long-term patient management, suggesting a need for enhanced surveillance in patients who have recovered from severe viral pneumonia. On a hopeful note, the study also found that vaccination appeared to mitigate this infection-enhanced tumor progression in the animal models, and that a combination therapy blocking both neutrophil recruitment and PD-L1 was able to suppress tumor growth. While that study looks at the long-term sequelae, a new trial in *The New England Journal of Medicine* provides a tool for immediate prevention [4]. This study focused on postexposure prophylaxis for COVID-19 in household contacts. The Study This was a double-blind, randomized, placebo-controlled trial in Japan. It enrolled household contacts of patients with confirmed COVID-19. Participants, who were themselves negative for SARS-CoV-2 at baseline, were randomized to receive either the oral antiviral ensitrelvir or a placebo within 72 hours of symptom onset in the index patient. The primary endpoint was the development of symptomatic COVID-19 by day 10. Results The trial included over 2000 participants. The incidence of COVID-19 was significantly lower in the group that received ensitrelvir. Only 2.9% of those on the drug developed COVID-19, compared to 9.0% in the placebo group. This translates to a risk ratio of 0.33, meaning the drug reduced the risk of developing symptomatic infection by about two-thirds. Importantly, adverse events were similar between the two groups, occurring in about 15% of participants in each arm, with serious adverse events being very rare. Conclusions The authors conclude that ensitrelvir is effective for postexposure prophylaxis in this setting. This gives clinicians a new, evidence-based option to offer household contacts to prevent the spread of COVID-19 and protect vulnerable individuals. Next, we turn to the fundamental pillars that support long-term health, with new data on sleep, mental health, and the immune system. A large-scale study in *Nature* introduces a concept called the 'Sleep Chart' to assess the link between sleep duration and biological aging [2]. Using data from the UK Biobank, researchers analyzed self-reported sleep duration against 23 different biological aging clocks derived from brain imaging, plasma proteomics, and metabolomics. They found a consistent U-shaped pattern across all measures. Biological aging was minimized with sleep durations between 6.4 and 7.8 hours per night. Both short sleep, defined as less than 6 hours, and long sleep, more than 8 hours, were associated with accelerated biological aging. These sleep patterns were also linked to an increased risk of systemic diseases, particularly depression and diabetes, as well as all-cause mortality. Interestingly, the mechanism appears to differ: for long sleepers, the path to depression seems to be partially mediated by accelerated aging, whereas for short sleepers, the link was more direct. This study provides strong, multi-system evidence to reinforce our clinical advice, giving us a specific, data-backed target for optimal sleep duration. Complementing this focus on fundamental wellness is a comprehensive review of Post-Traumatic Stress Disorder in *Nature Reviews Disease Primers* [1]. The review serves as a powerful reminder of PTSD's prevalence and systemic impact. The lifetime prevalence worldwide is estimated at 4 to 6 percent, but this can rise to as high as 25 to 30 percent in populations exposed to severe trauma, such as combat veterans and assault victims. While family physicians are familiar with the core psychiatric symptoms—intrusive memories, avoidance, negative mood, and hyperarousal—the review emphasizes that PTSD is a leading cause of suicide and is highly comorbid with depression, anxiety, and substance use disorders. Critically for primary care, it also increases the risk of multiple medical problems, including cardiovascular and metabolic disorders. This underscores the importance of viewing PTSD not just as a mental health condition, but as a systemic illness that requires diligent screening and integrated care in the primary care setting. Finally, delving deeper into the drivers of our baseline health, a study in *Cell* explores the relationship between our immune system and our gut microbiome [10]. By performing multi-omic profiling on 110 healthy individuals over more than a year, researchers found that the interferon response—a critical pathway for antiviral defense—was one of the most variable immune features between different people. However, within a single individual, this interferon setpoint was remarkably stable over time. This inter-individual variability was found to be strongly coordinated with the person's gut microbiome composition and its metabolic products. While foundational, this work begins to explain the vast differences we see in clinical practice regarding susceptibility to infections and responses to therapies. It suggests our unique microbiome helps establish our personal immune tone, a concept that will likely become increasingly important for personalized medicine. Our final theme this week looks at how the practice of medicine is broadening its focus, with papers on health systems, access to care, and our profession's role in planetary health. A landmark piece of guidance from the GRADE Working Group, published in the *Annals of Internal Medicine*, formally addresses how to integrate planetary health into clinical and public health guidelines [5]. Recognizing that human health is intrinsically linked to the health of natural systems, the guidance provides a framework for guideline developers to consider the environmental impact of their recommendations. This includes factors like climate change contributions, pollution, and the introduction of entities like microplastics. The new guidance states it is highly desirable for guideline panels to formally address these planetary health impacts, or to explicitly justify their exclusion. In practice, this means future evidence-to-decision frameworks may systematically weigh the carbon footprint of different inhalers or the plastic waste generated by a diagnostic test alongside traditional factors like efficacy and cost. This represents a significant shift in how evidence-based medicine will be defined and practiced. This theme of a broader, systems-level view is also reflected in a new *Lancet* Commission report focused on implementing sustainable liver health strategies across Europe [7], further signaling a move towards proactive, population-scale health policy. At the same time, other papers focus on improving systems of access to essential care. A viewpoint in *JAMA Internal Medicine* discusses the responsible implementation of self-collected HPV testing for cervical cancer screening [6]. The authors argue that while this technology holds immense promise for reducing health disparities, its rollout must be carefully planned to ensure it reaches underserved populations and truly narrows the screening gap. This is a call to be deliberate about equity when introducing new health technologies. In a similar vein, a research letter in *JAMA* investigates the real-world impact of policy changes on medication access, specifically examining changes in mifepristone use at pharmacies after the FDA removed its in-person dispensing requirement [8]. Both pieces highlight that clinical innovation and policy decisions must be coupled with a focus on equitable implementation to achieve their full potential. If you only have time for one paper this week, make it the study in *Cell* linking severe respiratory viral infections to accelerated lung cancer growth [9]. This finding establishes a new, critical long-term risk to monitor in patients who have recovered from severe pneumonia, including from COVID-19, and underscores the importance of vaccination as a potential mitigator. Here are the key takeaways from this week in Family Medicine. First, for household contacts of a patient with COVID-19, consider prescribing the oral antiviral ensitrelvir within 72 hours of the index patient's symptom onset. It was shown to reduce the risk of developing symptomatic disease by about two-thirds [4]. Second, when counseling on sleep, you can now cite evidence for a specific target of roughly 6.5 to 8 hours per night. New data from *Nature* ties both shorter and longer sleep durations to accelerated biological aging and chronic disease risk [2]. Third, be aware that patients with a history of severe pneumonia, including from COVID-19, may be at an increased risk for subsequent lung cancer. This finding from *Cell* may warrant heightened long-term surveillance in this population [9]. Fourth, remember that PTSD is a systemic illness linked to increased cardiovascular and metabolic risk. This reinforces the importance of screening and integrated management within primary care [1]. And finally, expect to see future clinical guidelines incorporate the environmental impact of medical interventions, as the official GRADE working group has now issued formal guidance on integrating planetary health into their frameworks [5]. That's your roundup for This Week in Family Medicine. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.